Live Breaking News & Updates on Presentation At American Academy Of Neurology

Horizon Therapeutics: New Long-Term Data for UPLIZNA (inebilizumab-cdon) in People Living with Neuromyelitis Optica Spectrum Disorder (NMOSD)
UPLIZNA continues to lower the rate of NMOSD attacks throughout the four-year open-label period (OLP)
Results from NMOSD patient survey describe long and daunting journey to diagnosis
Horizon Therapeutics plc (Nasdaq: HZNP) today announced new UPLIZNA (inebilizumab-cdon) data being presented at the American Academy of Neurology s 73rd Annual Meeting being held virtually April 17-22, 2021 (AAN 2021), including new, end-of-study data from the open-label extension period of the pivotal N-MOmentum trial in patients with NMOSD. UPLIZNA is the first and only FDA-approved anti-CD19 B-cell depleting humanized monoclonal antibody for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody positive NMOSD. ....

United States , Neuroimmunol Neuroinflamm , Quinn Dinh , Ruth Venning , Tina Ventura , Bruce Cree , Ray Gordon , Rachel Vann , Product Communications , Americas Committee For Treatment , American Academy Of Neurology , Presentation At American Academy Of Neurology , Research In Multiple Sclerosis , American Academy , Annual Meeting , California San Francisco Weill Institute , Maintained Throughout , Four Year Open Label , Americas Committee , Multiple Sclerosis , Pain Numeric Rating Scale , Neuromyelitis Optica Spectrum Disorder , Hepatitisb Virus , Progressive Multifocal Leukoencephalopathy , Prescribing Information , Neuropathic Pain ,